Table 1:

mRNA levels adjusted to GAPDH (x1000) of angiogenesis and vascular behavior-assoicated genes in tumor vasculature from vehicle and ZD6474-treated tumors.

Gene	B16.F10 melanoma		Lewis Lung Carcinoma
	Vehicle	Vandetanib	Vehicle	Vandetanib
CD31	6.40 ± 3.26	5.79 ± 2.34	109.16 ± 16.22	133.07 ± 40.42
VEcad	5.33 ± 4.36	3.16 ± 2.13	165.95 ± 72.60	169.18 ± 53.22
vWF	1.65 ± 0.71	2.67 ± 2.12	66.33 ± 40.42	89.93 ± 54.54
Itgαv	1.06 ± 0.31	1.36 ± 0.60	22.95 ± 6.93	22.36 ± 8.69
Itgβ3	0.96 ± 0.76	0.42 ± 0.10	46.88 ± 17.76	15.91 ± 7.76
HIF1α	3.48 ± 1.19	3.79 ± 1.09	32.66 ± 20.46	35.36 ± 10.43
VEGF-A	0.77 ± 0.24	1.37 ± 1.31	42.95 ± 10.31	50.59 ± 20.70
PlGF	1.61 ± 1.46	0.52 ± 0.24	8.11 ± 4.02	4.89 ± 2.09
VEGFR1	0.66 ± 0.40	0.67 ± 0.27	27.03 ± 6.79	22.12 ± 12.99
VEGFR2	1.17 ± 0.97	0.76 ± 0.36	72.96 ± 20.07	50.05 ± 20.32
CD105	9.09 ± 2.75	11.52 ± 4.28	85.64 ± 58.69	120.25 ± 69.03
eNOS	0.26 ± 0.07	0.61 ± 0.18	10.60 ± 4.88	12.86 ± 9.12
Robo1	0.18 ± 0.07	0.23 ± 0.11	1.00 ± 0.20	0.71 ± 0.25
MMP9	ND	0.15 ± 0.03	22.67 ± 17.75	24.01 ± 7.28
PCNA	23.53 ± 4.85	21.62 ± 4.16	24.13 ± 10.28	21.85 ± 5.92
Ang1	ND	ND	1.27 ± 0.83	1.43 ± 0.69
Ang2	1.12 ± 0.57	0.58 ± 0.36	30.05 ± 5.81	10.09 ± 2.70
Tie2	ND	0.57 ± 0.35	3.68 ± 1.60	12.78 ± 5.89
Notch3	0.68 ± 0.39	0.98 ± 0.57	7.79 ± 3.83	7.05 ± 4.65
Jag1	1.02 ± 0.59	1.08 ± 0.62	38.72 ± 7.32	46.13 ± 23.13
PDGF-B	3.67 ± 2.43	3.49 ± 2.95	62.32 ± 22.85	35.56 ± 28.45
PDGF-Rβ	1.40 ± 0.61	1.08 ± 0.44	43.41 ± 9.72	26.50 ± 9.00
Desmin	0.15 ± 0.08	0.14 ± 0.05	0.63 ± 0.22	4.61 ± 5.75
αSMA	16.50 ± 6.21	13.35 ± 7.49	28.61 ± 10.06	42.45 ± 31.00
N-cad	3.93 ± 1.13	4.48 ± 0.60	1.54 ± 0.69	4.50 ± 1.34
P-sel	0.21 ± 0.17	3.53 ± 1.25	1.27± 0.63	17.84 ± 6.22
E-sel	ND	0.65 ± 0.10	0.73 ± 0.01	2.53 ± 1.77
VCAM-1	0.28 ± 0.07	0.37 ± 0.10	67.87 ± 22.36	82.95 ± 28.83
ICAM-1	0.61 ± 0.38	0.83 ± 0.25	7.47 ± 2.02	13.20 ± 9.30